Imagine a treatment that activates your own immunity to target lung cancer, causing almost no side effects and allowing you to maintain your usual rhythm of life. Dendritic cell therapy opens up this possibility for patients at different stages of the disease, demonstrating an effectiveness of 50-65% for different types of tumors.
Lung cancer is diagnosed in 226,650 new patients each year [1], and survival rates vary from 77% in the early stages to 21% in the late stages [3]. That is why German clinics are actively implementing this personalized form of immunotherapy.
To ensure maximum accuracy, doctors develop an individual dendritic cell vaccine. Lung cancer patients benefit from such an approach because the vaccine is created taking into account the unique characteristics of the tumor cells. Unlike traditional methods that damage healthy tissues along with tumor ones, this approach "teaches" the immune system to recognize and destroy only malignant cells.
The procedure involves only two outpatient visits: consultation, blood collection, and injection after a week of preparation of the vaccine. At the same time, patients usually maintain their usual lifestyle, including physical activity. Because the therapy affects the immune response, it can be used either alone or in combination with classical treatment, opening up new possibilities even in difficult cases.
Understanding Lung Cancer: Types and Stages
Lung cancer is divided into two main types: non-small cell lung cancer (NSCLC), which accounts for about 87% of cases, and small cell lung cancer (SCLC) – about 13%. NSCLC is more frequent and usually progresses more slowly than SCLC [1].
Doctors use staging to assess the spread of the disease. In the early stages, the tumor is limited to the lungs, while in the late stages, it spreads to the lymph nodes or distant organs [2].
Survival rates largely depend on stage at diagnosis [3]:
- early stage – about 67% five-year survival rate;
- spread to neighboring structures – about 40%;
- distant metastases – about 12%.
The American Cancer Society estimates that about 226,650 new cases of lung cancer are expected in 2025. The disease is mainly diagnosed in older people, most often about 70 years old. While these statistics may seem concerning, survival rates are improving thanks to better treatments and earlier detection methods. [1]
Current treatments, particularly dendritic cell lung cancer treatment, modulate the anti-tumor immune response and open up new opportunities for patients at different stages of the disease.
Each patient's situation is unique, and treatment decisions should always be made in consultation with experienced oncologists who can provide personalized care based on individual circumstances and the specific characteristics of each cancer case.
The Science Behind DC Therapy for Lung Cancer
The scientific foundation for this approach was established by 2011 Nobel Prize winner Ralph Steinman, whose groundbreaking research demonstrated how dendritic cells function as the immune response commanders. His work showed how this method acts as the body's security system, identifying threats and coordinating the immune response. [4]
Understanding Dendritic Cells
Dendritic cells are specialized white blood cells that serve as the connection between your body's immediate defense system and its more targeted immune responses. Within the framework of dendritic cells in lung immunopathology, they act as the primary sensors of the immune system in the respiratory environment. Think of each lung dendritic cell as a highly trained security officer who can recognize dangerous intruders and then alert the entire security force about what to look for.
Modern immunological research allows us to understand much more deeply the specific role of dendritic cells. Lung cancer remains an area where scientific evidence confirms that these immune cells play a crucial role in recognizing cancer antigens – unique markers on the surface of tumor cells.
The natural cancer-fighting process works through a coordinated sequence where lung dendritic cells capture information about the cancer and present it to T-lymphocytes (the immune system's attack cells). The interaction between lung dendritic cells and T cell differentiation is vital: once T-lymphocytes receive this information, they actively seek out and destroy cancer cells while teaching other immune cells what to target and creating a robust immune response. [5]
The main challenge in cancer treatment is that the immune response often doesn't naturally recognize cancer cells as threats. Cancer cells can disguise themselves and avoid detection by the immune system, allowing tumor cells to grow undetected. This is where dendritic cells in treatment of lung cancer become a valuable method.
How Dendritic Cell Therapy Works in Lung Cancer
The usage of dendritic cells in treatment of lung cancer in Germany is based on a high-tech process that allows the patient's immune system to fight the tumor on its own. The procedure consists of the following stages:
- Collection. Dendritic cells are gathered from the patient's blood through a simple procedure.
- Education. They are trained in the laboratory to recognize specific lung cancer characteristics using tumor cells’ antigens and boost the immune response.
- Reintroduction. The educated dendritic cells are returned to the patient's body through injection.
- Activation. They act as instructors for all immunity, stimulating the patient`s natural dendritic cells. Lungs become the site of an active immune response, where the system learns to unmistakably identify and attack cancer cells, while forming a long-term and sustainable defense.
In fact, therapy "teaches" the immune system to recognize cancer, forming a more accurate and effective response against lung cancer. This approach interacts with the body's natural defense mechanisms and can provide better results with fewer side effects compared to traditional treatment alone.
The "education" stage — loading dendritic cells with tumor antigens — relies on liquid biopsy to isolate relevant antigens directly from the patient's blood. The quality of antigen representation depends on circulating tumor cell concentration and whether prior chemo or targeted therapy has altered the tumor's surface antigens.
Booking Health's pre-treatment case review identifies the patient's current treatment status and ensures that the liquid biopsy yields a representative antigen source at that moment.
CHECK IF A BETTER SOLUTION EXISTS FOR YOUPatient Selection Criteria for Dendritic Cell Therapy in Lung Cancer
Dendritic cell therapy offers hope for a wide range of lung cancer patients. Unlike many conventional treatments that have strict eligibility requirements, the DC vaccine against lung cancer safely affects the immune response and can be considered for patients at all stages of lung cancer, from early-stage disease to advanced metastatic cases. Even patients who have already exhausted other treatment options or cannot tolerate aggressive standard therapy are candidates for dendritic cell therapy. [7]
Medical Evaluation Process
The selection of patients is usually based on several key criteria that doctors assess during the initial consultation. The patient's recent medical records provide essential information about their current condition and treatment history. Laboratory tests help determine if the immune system has enough resources to effectively support dendritic cell treatment. Lung cancer treatment does not require the patient to have ideal health indicators, but examination before this procedure is extremely important. Doctors assess whether patients can safely undergo the blood collection procedure required to obtain dendritic cells.
Ideal Lung Cancer Candidates for DC Treatment
The following factors support candidacy for DC therapy for lung cancer in Germany:
- Any cancer stage: From early-stage tumors following surgery to advanced metastatic disease
- Previous treatment history: Patients who have received chemotherapy, radiation, or surgery remain eligible
- Compromised health status: Even debilitated lung cancer patients may benefit
- Treatment resistance: Patients whose cancers no longer respond to conventional therapies are eligible
- Combination approach: Those seeking to enhance the effectiveness of current treatments by boosting the natural immune response
The individualized nature of DC therapy means that treatment plans are customized based on each patient's specific tumor cells’ characteristics and health condition. This personalized approach allows doctors to create a DC vaccine against lung cancer tailored to the unique features of each patient's cancer, making the anticancer immune response possible even in challenging cases where standard treatments have limited success.
"Even debilitated patients may benefit" is clinically true. But determination requires current blood parameters, not the patient's general health assessment.
Booking Health verifies monocyte count and immune function markers before the program is confirmed — so that the two-visit protocol the patient is committing to is one that can be completed successfully.
GET A SECOND OPINION FOR YOUR CASECost of Dendritic Cell Therapy for Lung Cancer
One of the decisive factors when choosing a place to undergo innovative treatment, such as dendritic cell therapy (DCT), is financial availability without losing the quality of medical services. A comparative analysis of the global health services market demonstrates that Germany currently offers the most balanced conditions for patients diagnosed with lung cancer.
According to the latest data, the price range for a full course of dendritic cell therapy varies significantly depending on the region:
Comparison of treatment costs in different countries
| Country | Estimated cost of the course |
|---|---|
| Germany | €20,000 – €38,000 |
| UK | Not available |
| USA | €100,000 – €150,000 |
| Australia | Not available |
Why are prices in Germany the most optimal?
Germany holds the lead in immunotherapy through several key aspects, allowing doctors to successfully apply individual vaccines based on the function of a dendritic cell. Lung cancer treatment in Germany is becoming much more accessible to international patients thanks to the following factors:
- Availability of technology: As Germany is one of the centres for biotechnology development in Europe, most laboratories for the manufacture of individual vaccines are located in the country. This significantly reduces logistics costs.
- Transparent pricing: Unlike the US, where the cost of similar treatment can reach more than €100,000 due to high administrative costs and features of the insurance system, German clinics operate on clear protocols with a projected budget.
- High standard GMP: Despite the lower price (compared to the States), the quality of manufacturing of cellular drugs in Germany meets the strictest standards of the European Union (Good Manufacturing Practice), which guarantees the safety and effectiveness of therapy.
The €20,000-38,000 range represents Germany's rate for locals.
Patients who arrive through Booking Health's direct contracts pay that rate without the additional mark-up clinics apply to international patients — a surcharge that sits outside Germany's regulated pricing framework and is not visible in published tariffs. Beyond the price itself, every program includes a fully itemized budget confirmed before commitment, complication insurance of €200,000 as standard, and return of any unspent balance after the program concludes.
For UK and Australian patients, Germany is not the affordable option — it is the only option.
What Does the Dendritic Cell Vaccination for Lung Cancer Involve?
Modern German medical centers offer patients a highly effective and safe dendritic cell therapy lung cancer. Germany provides the opportunity to undergo this treatment fully on an outpatient basis: you visit the clinic, receive the necessary procedures, and return home the same day, while your immune system begins an active fight against the tumor.
Step 1: Your First Visit
During your first appointment, your doctor will examine your medical history and conduct a basic examination. Standard blood tests are also performed to assess overall health and determine the feasibility of therapy.
After that, 150-200 ml of blood is taken, approximately, as with a regular donation. It contains tumor antigens and immune cells that are used to create a personalized vaccine based on dendritic cells.
Step 2: Creating Your DC Vaccine
The laboratory needs seven days for trained dendritic cell development and preparation of your individual DC vaccine. This stage is the foundation for conducting the most effective dendritic cell therapy for lung cancer. Germany offers unique conditions for treatment, as doctors use the liquid biopsy method to isolate relevant tumor antigens directly from your blood sample. This approach provides "training" immune cells to recognize relevant features of the tumor, which contributes to the formation of a more powerful immune response.
During this period, immune cells are programmed to detect and destroy lung cancer cells. The entire process of preparing dendritic cells takes place in the laboratory, while the patient can continue his usual life at home.
Step 3: Receiving Your Treatment
After one week, the patient returns to the clinic for a simple injection. The dendritic cell-based vaccine is administered subcutaneously near lymph nodes. The procedure is fast and well-tolerated, and most patients do not note significant side effects.
You'll stay under medical supervision for a short time after the injection, but there's no need for hospitalization. A complete treatment course requires only one injection to build strong cell immunity against your cancer.
The entire procedure is designed to work with your body's natural immune response while causing minimal disruption to your daily life.
Treatment Outcomes by Lung Cancer Stage
The goals of administering the lung cancer vaccine differ depending on the stage of lung cancer and previous treatment:
- Vaccination for early-stage cancer helps a patient to enter remission by destroying the atypical cells remaining after the operation. A prerequisite, in this case, is surgical tumor removal because the DC vaccine will not be able to destroy large malignant foci in the lung tissue.
- Vaccination for stage 4 cancer suppresses the growth of existing metastases and the formation of new ones. In such a situation, doctors seek to relieve symptoms (for example, improving respiratory function or reducing the risk of bleeding) and better control the disease.
- The administration of a dendritic cell vaccine also serves as a prevention of cancer recurrence as it promotes the development of immune memory, and new cells with similar malignant mutations will be quickly destroyed [10].
Another promising application of dendritic cells for advanced lung cancer is their combination with the Newcastle disease virus and T-cell therapy. In studies, combination treatment has shown the highest efficacy in patients with advanced cancer.
Hospital Selection for Dendritic Cell Therapy for Lung Cancer
Choosing a medical center for DCT is a crucial step that determines not only the patient’s comfort but also the immediate success of the treatment. It is important to understand that DCT is a high-tech method that is not implemented in every clinic.
Hospital selection criteria: experience and international status
When choosing a hospital for the treatment of lung cancer with DC therapy, we focus on two main aspects:
- Specialization in immunotherapy: We choose centers that have many years of experience in the application of DCT for pulmonary pathologies. This ensures that doctors understand the specifics of the body's response to the vaccine in different stages of cancer.
- Experience with international patients: At any hospital, Booking Health ensures there are no language barriers, that medical records are promptly translated, and that the organizational needs of patients arriving from abroad are fully understood.
Thanks to this multi-stage approach, the patient receives not just "treatment", but a comprehensive solution in the best medical center that corresponds to his individual clinical case.
Professional Medical Opinions on Dendritic Cell Therapy in Lung Cancer
Professor Frank Gansauge, from the LDG laboratories in Germany, has over 22 years of experience, particularly in the application of dendritic cells for the treatment of cancer. His clinic has been engaged in this immunotherapy since 2001 and is one of the first private laboratories to introduce vaccination with dendritic cells.
According to Prof. Gansauge, dendritic cell therapy demonstrates effectiveness rates of 50-65% across various cancer types, including lung cancer. "Already after three months, a doctor can see whether the patient's condition has improved," he notes, with outcomes measured through imaging studies that assess complete tumor disappearance, shrinkage, or stability.
The clinic has demonstrated significant increases in average life expectancy for lung cancer patients and achieved complete responses in some cases, with patients showing no tumor recurrence after five years. Professor Gansauge's approach is based on the creation of personalised dendritic cell-based vaccines adapted to the specific tumour antigens of each patient.
Prof. Gansauge emphasizes that DCT causes "practically no side effects" according to his clinical experience. The German regulatory framework ensures manufacturing standards under the supervision of the European Medicines Evaluation Agency and the Paul Ehrlich Institute, providing rigorous quality control for dendritic cell vaccine production.
Professor Gansauge emphasizes that dendritic cell therapy should be carried out only in institutions with proper regulatory approval for vaccine production. He also notes that Germany has strict regulatory measures in place to ensure the safety and efficacy of this innovative cancer immunotherapy.
VIDEO
Expert Insights from
Prof. Gansauge:
The Power of Dendritic Cell Therapy in Cancer Treatment
Dendritic Cell Therapy
BOOK CONSULTATION
Comparing Treatment Options: Dendritic Cells vs. Traditional Lung Cancer Therapies
Understanding different treatment approaches helps patients and their families make informed decisions about lung cancer therapy. Each method has its advantages, and the best results are usually achieved by combining several treatment strategies.
Treatment Comparison: Key Differences and Benefits
| Aspect | Dendritic Cell Therapy | Surgery | Chemotherapy | Radiation Therapy |
|---|---|---|---|---|
| Treatment Type | Immunotherapy using the patient`s own cells | Physical tumor removal | Chemical drugs | High-energy radiation |
| Side Effects | Minimal to none | Surgical risks, recovery time | Severe: nausea, hair loss, fatigue | Fatigue, skin irritation, and breathing issues |
| Hospital Stay | Outpatient, same day | Several days to weeks | Outpatient cycles | Daily sessions for weeks |
| Hair Loss | No hair loss | No hair loss | Complete hair loss is common | Possible in the treatment area |
| Immune System | Strengthens natural cell immunity | No cell immunity impact | Weakens the immune response | May affect cell immunity function |
| Cancer Stage | All stages, including advanced | Early to mid-stage only | All stages | Localized areas |
| Personalization | Fully customized to the patient`s tumor | Standard surgical approach | Standard drug protocols | Standard radiation doses |
| Long-term Protection | Creates immune memory, lifelong cell immunity | No ongoing protection | No ongoing protection | No ongoing protection |
Real Lung Cancer Patient Stories and Outcomes
Susan Clark Livingston from the USA underwent dendritic cell therapy at LDG Laboratories Dr. Gansauge Berg in Germany, after diagnosis of advanced lung cancer. Doctors in the USA predicted her life expectancy to be about six months.
At the time of this story, Susan exceeded her initial prognosis by a year and a half, continuing her treatment with dendritic cells. Her family member described her current condition: "By the way, she still looks fabulous, she has a full, beautiful mane of red hair, and she's still the same waist size she was as a teenager. Despite the lung cancer, she's still going for a run almost every morning, and looks as good as she did twenty-two years ago."
The treatment took place in facilities described by her family as comfortable and non-clinical in atmosphere. "The facilities are comfortable. It doesn't feel like a scary hospital room. It's sunny, beautiful, and homey." The medical team led by Prof. Dr. Gansauge and Dr. Taubert, provided comprehensive support with the participation of coordinators Claudia and Julia, who helped organize the treatment process.
Susan's family noted several important aspects of her experience:
- Preservation of physical condition: she continues her morning runs and keeps in shape despite an advanced illness.
- No hair loss: unlike chemotherapy, it retained thick red hair.
- Active daily life: without significant restrictions in daily activities.
- Clinic support: a combination of medical care and emotional support.
- Organization of treatment abroad: assistance to personnel in solving logistical issues.
Her family expressed confidence in the chosen therapy, noting: "I have complete confidence in your program and believe that the treatment will continue to work". The case was managed by Prof. Dr. Gansauge and Dr. Taubert at the German facility, with Susan receiving the personalized dendritic cell therapy protocol developed specifically for her lung cancer case.
"Thanks to the brilliance and diligence of Professor Gansauge and Dr. Taubert, my mother has outlived her original diagnosis by a year and a half," Julia shared.
Before Julia's logistical arrangements began — flights, accommodation, the coordinators Claudia and Julia — Booking Health reviewed Susan's staging data, prior treatment history, and immune function parameters to confirm that her profile supported effective vaccine preparation at LDG.
The comfort of the facility and the quality of the medical team Julia describes were the clinical environment. The case review that matched Susan to that environment came first, and it was completed within 24 hours of receiving her record.
Getting Dendritic Cell Treatment for Lung Cancer in Germany
Dendritic cell therapy in lung cancer is an alternative approach that can help control symptoms, particularly pain, and potentially improve prognosis by activating the immune system against tumor cells. This method stimulates the body's natural defense mechanisms and promotes the formation of the immune response to cancer.
Although the results may differ in each patient, among the possible benefits is a more targeted effect on the tumor and a likely lower number of side effects compared to traditional treatment.
Treatment Availability in German Medical Facilities
DC therapy for lung cancer is available in German clinics for foreign patients regardless of their country of residence. Treatment involves creating a personalized vaccine using the patient's own immune cells and tumor material, requiring specialized laboratories and an experienced medical team.
Clinics in Germany usually provide a comprehensive oncology approach, combining this immunotherapy with surgery, chemotherapy, or radiation therapy. Individualization of treatment means that the therapeutic plan is formed taking into account the characteristics of the tumor and the general condition of the patient.
Support Services for International Lung Cancer Patients
Booking Health helps foreign patients access dendritic cell therapy. With over 12 years of experience in organising lung cancer treatment in Germany, the company acts as a mediator between patients and specialist clinics. The cost of treatment can be checked on the website, while transparent pricing is ensured without hidden fees.
Support for foreign patients usually includes:
- selection of clinics and doctors specializing in dendritic cell therapy;
- preliminary online consultations;
- development of an individual treatment program;
- organisation of hospital admission due to urgency;
- independent medical support and quality control;
- post-treatment support, including medicines;
- management of bills and financial matters;
- organisation of additional examinations or rehabilitation;
- trip coordination (flight, accommodation, transfers);
- interpreter services during treatment.
Coordinators accompany the patient at all stages – from referral to homecoming, covering both medical and organizational aspects of treatment abroad.
Booking Health holds ISO 9001 quality certification, reflecting well-established processes and strict quality control at every stage of the treatment journey — not just at the initial consultation, but throughout.
Personalized Dendritic Cell Treatment: Experience with Booking Health
FAQ About Lung Cancer Therapy with Dendritic Cells
Dendritic cells play a key role in the immune response by recognizing and presenting cancer cells to the immune system. In the treatment of lung cancer, they are modified to target tumor cells, strengthening the body's ability to fight the disease.
Advantages include a personalized and targeted approach, fewer side effects compared to traditional methods, and the potential for long-term remission. Such therapy may be particularly useful in patients with advanced or metastatic lung cancer.
The process involves taking dendritic cells from the patient, modifying them to recognize lung cancer cells, and then returning them to the body. This activates the immune system to attack tumor cells more effectively.
Success rates depend on the patient's individual characteristics and the stage of the disease. At the same time, many patients report significant improvement in their condition, and some achieve long-term remission.
Most side effects are mild and temporary, including fever and fatigue. Serious complications are rare but require careful medical monitoring during treatment.
Dendritic cell therapy is a personalized immunotherapy that «teaches» the immune system to recognize and destroy cancer cells using the patient's own immune cells, modified in the laboratory to take into account the characteristics of their tumor.
Yes, this treatment is used both for non-small cell lung cancer (about 87% of cases) and for small cell lung cancer (about 13%), regardless of the stage of the disease, including advanced forms and stage IV.
The full course involves only two outpatient visits: the first for consultation and blood collection, the second for injection after a week of vaccine preparation, making the process convenient for the patient.
Germany has best practices in this area and provides strict regulatory control that guarantees the safety and quality of treatment. In addition, specialized oncology clinics with experienced teams provide comprehensive medical care.
Therapy consists of creating personalized vaccines based on the unique properties of tumor cells, «teaching» the immune system to respond effectively to specific markers of both types of lung cancer.
Patients can be eligible at any stage of the disease, including those who have exhausted other treatment options, cannot tolerate aggressive therapy, or seek to improve outcomes through personalized approaches.
Yes, combined treatment is possible and often appropriate: this immunotherapy can enhance the effect of traditional methods, potentially reducing side effects and improving overall outcomes.
Studies show efficacy at 50-65%, with patients able to maintain usual activity, including exercise, and usually having fewer side effects compared to traditional treatment.
Yes, German clinics offer this treatment within the framework of specialized immunotherapy programs for foreign patients, regardless of their nationality, also providing comprehensive support.
The dendritic therapy cost ranges from €20,000 to €38,000, with transparent pricing and support services helping manage medical travel.
The cost depends on the complexity of the case and the individual treatment plan. It includes the preparation of the vaccine, a doctor's consultation, and the administration of the cells according to GMP standards.
Unlike surgery, chemotherapy, or radiotherapy, dendritic cell therapy activates the immune system to recognize and destroy cancer cells on its own. The treatment is personalized and safe.
Dendritic cell therapy has almost no side effects: patients may experience mild fatigue or a slight increase in temperature, unlike chemotherapy with nausea, hair loss, and immune suppression.
No, the procedure is performed on an outpatient basis. The patient comes in for a blood draw and a vaccine, and then goes home the same day. Unlike surgery or radiotherapy, there is no need to stay in the hospital.
No, the therapy does not cause hair loss. Because it stimulates the immune system, the patient maintains a normal appearance and can lead a normal lifestyle during treatment.
Yes, it can be used at any stage of the disease and combined with surgical treatment, chemotherapy, or radiation therapy to increase effectiveness.
Yes, therapy shapes immune memory: the body is able to recognize and destroy cancer cells when they reappear. This helps reduce the risk of recurrence and promotes long-term disease control.
Choose treatment abroad and you will for sure get the best results!
Sources:
01. Siegel RL, Kratzer TB et al. Cancer statistics, 2025. CA Cancer J Clin. 2025 Jan 16;75(1):10–45. doi: 10.3322/caac.21871. [DOI] [PubMed] [PMC free article]
02. Dela Cruz CS, Tanoue LT, Matthay RA. Lung Cancer: Epidemiology, Etiology, and Prevention. Clin Chest Med. 2011 Dec;32(4):10.1016/j.ccm.2011.09.001. doi: 10.1016/j.ccm.2011.09.001. [DOI] [PubMed] [PMC free article]
03. He S, Li H et al. Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China. Transl Lung Cancer Res. 2022 Aug;11(8):1591–1605. doi: 10.21037/tlcr-22-240. [DOI] [PubMed] [PMC free article]
04. Volchenkov R, Sprater F et al. The 2011 Nobel Prize in physiology or medicine. Scand J Immunol. 2012 Jan;75(1):1-4. doi: 10.1111/j.1365-3083.2011.02663.x. [DOI] [PubMed]
05. Salah A, Wang H et al. Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications. Front Cell Dev Biol. 2021 Jun 28:9:686544. doi: 10.3389/fcell.2021.686544. [DOI] [PubMed] [PMC free article]
06. Song MS, Nam JH, Noh KE, Lim DS. Dendritic Cell-Based Immunotherapy: The Importance of Dendritic Cell Migration. J Immunol Res. 2024 Apr 8;2024:7827246. doi: 10.1155/2024/7827246. [DOI] [PubMed] [PMC free article]
07. Stevens D, Ingles J et al. Dendritic Cell-Based Immunotherapy in Lung Cancer. Front Immunol. 2021 Feb 12;11:620374. doi: 10.3389/fimmu.2020.620374. [DOI] [PubMed] [PMC free article]
08. Marchelek EM, Nemeth A, Mohak S et al. Dendritic Cell Therapy in Immuno-Oncology: A Potentially Key Component of Anti-Cancer Immunotherapies. Cancers 2026, 18(1), 123; doi: 10.3390/cancers18010123. [DOI]
09. Hato L, Vizcay A et al. Dendritic Cells in Cancer Immunology and Immunotherapy. Cancers (Basel). 2024 Feb 28;16(5):981. doi: 10.3390/cancers16050981. [DOI] [PubMed] [PMC free article]
10. Barboza de Oliveira J, Silva SB et al. Dendritic cell-based immunotherapy in non-small cell lung cancer: a comprehensive critical review. Front Immunol. 2024 Sep 6;15:1376704. doi: 10.3389/fimmu.2024.1376704. [DOI] [PubMed] [PMC free article]
Read:
01. Lung Cancer Treatment in Germany: All New and Most Effective Treatment Options
02. Treatment of stage 4 lung cancer in Germany
03. Top 10 Leading Oncology Hospitals for Cancer Treatment in Germany: A 2026 Guide
